1.Expression and function of LETM2 in esophageal squamous carcinoma
Xiaoling HU ; Yuanfang ZHAI ; Jie YANG ; Juan WANG ; Yanghui BI ; Bin YANG ; Caixia CHENG ; Bin SONG ; Ling ZHANG ; Pengzhou KONG
Chinese Journal of Clinical Oncology 2017;44(8):355-359
Objective:To analyze the expression of LETM2 in KYSE150 and ECA109 cell lines and its effect on the proliferation, migra-tion, and invasion of esophageal squamous cell carcinoma (ESCC). Methods:The expression level of the LETM2 protein in 90 paired hu-man ESCC tissues and matched adjacent normal tissues was determined through immunohistochemistry. The expression level of LETM2 in ESCC cell lines was detected by real-time PCR and Western blot. The expression levels of LETM2 in KYSE150 and ECA109 cell lines were knocked down using lentivirus. MTT assays were performed to examine the effect of LETM2 on the proliferation of ESCC cells. Colony formation assay was used to detect the colony formation ability. Flow cytometry was performed to analyze the cell cycle. The effect of LETM2 depletion on the migration and invasion of ESCC cells was determined by Transwell assay. Results:LETM2 expres-sion was frequently upregulated in the ESCC tissues than in the adjacent normal tissues. The suppressed exogenous expression of LETM2 led to the inhibition of cell proliferation and colony formation. However, cell migration and invasion were not affected. The re-sults on the cell cycle distribution revealed that LETM2 knockdown acts as a negative regulator of the cell cycle at the G1 to S phase transition. Conclusion:LETM2 acts as a tumor-driven gene in the development and progression of ESCC. This finding suggests that LETM2 can be used as an efficient prognosis biomarker and a potential therapeutic target for ESCC.
2.Analysis of 15 183 Cases of ADR Caused by Antineoplastic Drugs
Wei KOU ; Daihong GUO ; Xiaoyan TIAN ; Wangping JIA ; Liang ZHAO ; Xiaoyu WANG ; Pengzhou HU
China Pharmacy 2018;29(4):508-511
OBJECTIVE: To investigate the characteristics and regularity of ADR induced by antineoplastic drugs and provide reference for safe drug use in clinic. METHODS: ADR reports induced by antineoplastic drugs reported by 108 hospitals during Jan. 2009-Dec. 2016 were collected from PLA ADR Monitoring Center. ADR reports were analyzed respectively in respects of types of ADR reports, patients ' gender and age, administration route, occurrence time, types of antineoplastic drug, the situation of patients suffering tumor, systems/organs involved in ADR, clinical manifestations, outcome, etc. RESULTS: Among 15 183 ADR reports, there were 462 cases of new ADR and 2 873 cases of severe ADR; there were 8 039 male (52. 95%) and 7 144 female (47. 05%). The proportion of severe ADR in female (20. 00%) was significantly higher than male (17. 96%), with statistical significance (P=0. 001). ADR was mainly induced by intravenous administration (90. 53%), and mainly occurred 2-<7 d after medication (23. 00%). Top 3 drug categories in the list of ADR were platinum antineoplastic drugs (25. 63%), plant-derived antineoplastic drugs and its derivative (24. 42%) and anti-metabolism drugs (18. 50%). Male patients mainly suffered from lung cancer, colorectal cancer and gastric cancer; female patients mainly suffered from breast cancer, lung cancer and colorectal cancer. Systems/organs involved in ADR were gastrointestinal system, hematological system and systemic damage. Main clinical manifestations were nausea, vomiting, myelosuppression, skin rash and fever. Totally 92. 57% of ADR cases were cured and recovered after treatment, and 5 cases died. CONCLUSIONS: Antineoplastic drugs have high incidence of ADR with serious damage. Clinic should strengthen the monitoring of key population and key drugs so as to reduce the occurrence of ADR.